Idiopathic pulmonary fibrosis is thought to involve lung injury caused by reactive oxygen species (ROS), which in turn is followed by abnormal fibrosis. Recent studies have found that mepenzolate bromide (mepenzolate), which has been used clinically to treat gastrointestinal disorders, has ROS-reducing properties. In the present study, the effect of mepenzolate on bleomycin-induced pulmonary fibrosis and lung dysfunction in mice was investigated. Intratracheal administration of mepenzolate prior to bleomycin treatment reduced the extent of pulmonary fibrosis and changes in lung mechanics and led to a significant recovery of both forced vital capacity and percutaneous arterial oxygen saturation compared with control. Furthermore, mepenzolate produced a therapeutic effect even when it was administered after the development of fibrosis. These effects may be attributed to this drug’s inhibitory effect on NADPH oxidase and transforming growth factor-β1 activities and its stimulatory effect on glutathione S-transferase.
See article at J Pharmacol Exp Ther 2014, 350:79–88.
- Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics